This is a summary of the European public assessment report (EPAR) for Clopidogrel ratiopharm. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide ... European Medicines Agency, 2 weeks ago
3 images for "clopidogrel"
Reuters Health Information By David Douglas February20,2015 NEW YORK (Reuters Health) - Users of clopidogrel and concomitant proton pump inhibitors (PPIs) are not at increased risk of ischemic stroke, according to researchers. "To exert its ...Diabetes Care, 1 month ago Aspirin resistance tied to more severe strokes UnitedHealthcare, 2 weeks ago Resistance To Aspirin May Point To Increased Risks Of Severe Stroke Tech Times, 1 month ago Study, Aspirin Resistance Is a Precursor to Stroke NewsHub South Africa, 1 month ago
More from: National Womens Health Information Center, National Womens Health Information Center...and 6 other sources
GETTING to the heart of medical matters Q I take clopidogrel and atorvastatin following a mini stroke. I now bruise easily and have very low cholesterol. With thinner blood is there more of a risk of a brain aneurysm-While lower cholesterol is ...Scottish Daily Express, 1 month ago
is a professional and in-depth market survey on Global and Chinese Clopidogrel bisulfate industry. The report firstly reviews the basic information of Clopidogrel bisulfate including its classification, application and manufacturing technology; The ...Individual.com, 1 month ago
DURHAM, NC — There is a disconnect between results derived from observational studies examining the safety of using proton-pump inhibitors (PPIs) with dual antiplatelet therapy and the results obtained from randomized, controlled clinical ...Dermatology Online Journal, 1 month ago
— Merck announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of Zontivity (vorapaxar), one of the largest secondary prevention studies ...Diagnostic & Invasive Cardiology, 3 weeks ago Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease TMC Net, 3 weeks ago Merck : Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease 4 Traders, 3 weeks ago Vorapaxar may reduce acute limb ischemia, peripheral revascularization in patients with PAD Orthopedics Today, 5 days ago
NICE recommends Xarelto (rivaroxaban) as an effective treatment option for reducing risk of secondary events in ACS
NICE FAD recommends 2.5mg Xarelto twice daily in combination with aspirin alone or aspirin plus clopidogrel or ticlopidine, as an option for secondary prevention following ACS in patients with elevated cardiac biomarkers, without prior stroke or ...FirstWord Pharma, 2 months ago NICE Recommends Xarelto®▼ (rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary … Yahoo! Finance, 2 months ago NICE Recommends Xarelto(R)a- 1/4 (rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary Events in ACS Individual.com, 2 months ago
More from: , Sys-Con Belgium...and 1 other sources
In final guidance published today NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare), in combination with clopidogrel and aspirin, or with aspirin alone, as an option for preventing blood clots in people who have had an acute coronary ...NICE, 4 days ago NICE decisions made on Bayer, Celgene and Boehringer drugs Pharmafocus, 3 days ago NICE recommends Bayer heart attack drug Pharmafocus, 2 months ago
More from: , FirstWord Pharma...and 2 other sources
1 , BARBARA SANDOR 2 , KAROLY KALMAR NAGY 1 , DORA PRAKSCH 2 , KATALIN GOMBOS 3 , ANDRAS TOTH 2 , KALMAN TOTH 2 and PETER SZAKALY 1 ⇑ 1 Department of Surgery, University of Pecs, School of Medicine, Pecs, Hungary 2 First Department of ...In Vivo, 1 week ago
NOVEL HIGH-POTENCY ORAL ANTIPLATELET DRUGS VERSUS CLOPIDOGREL IN PATIENTS UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A LARGE SINGLE-CENTER ALL-COMERS REGISTRY
on your WebpageAdd Widget >Get your members hooked!